JSKN 021
Alternative Names: JSKN-021Latest Information Update: 25 Jun 2026
At a glance
- Originator Alphamab Oncology
- Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Jun 2026 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT07617727) (Alphamab Oncology pipeline, June 2026)
- 31 May 2026 Jiangsu Alphamab Biopharmaceuticals plans a phase I trial in Solid tumours (Late-stage disease) (IV) (NCT07617727)
- 25 Apr 2025 Pharmacodynamics data from preclinical studies in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)